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The mutation and overexpression of the epidermal
growth factor receptor (EGFR) are associated with
the development of a variety of cancers, making
this prototypical dimerization-activated receptor
tyrosine kinase a prominent target of cancer drugs.
Using long-timescale molecular dynamics simula-
tions, we find that the N lobe dimerization interface
of the wild-type EGFR kinase domain is intrinsically
disordered and that it becomes ordered only upon
dimerization. Our simulations suggest, moreover,
that some cancer-linked mutations distal to the
dimerization interface, particularly the widespread
L834R mutation (also referred to as L858R), facilitate
EGFR dimerization by suppressing this local dis-
order. Corroborating these findings, our biophysical
experiments and kinase enzymatic assays indicate
that the L834R mutation causes abnormally high
activity primarily by promoting EGFR dimerization
rather than by allowing activation without dimeriza-
tion. We also find that phosphorylation of EGFR
kinase domain at Tyr845 may suppress the intrinsic
disorder, suggesting a molecular mechanism for
autonomous EGFR signaling.INTRODUCTION
Epidermal growth factor receptor (EGFR), one of the most
studied receptor tyrosine kinases, represents both a prototypical
cell-surface receptor and a prime cancer drug target. The EGFR
family (that also includes three other members, Her2–4), plays
a critical role in the regulation of cell proliferation, differentiation,
and migration (Yarden and Sliwkowski, 2001).
The mutation and overexpression of EGFR receptor tyrosine
kinases have been implicated in the growth of a host of human860 Cell 149, 860–870, May 11, 2012 ª2012 Elsevier Inc.cancers, and a number of EGFR and Her2 inhibitors are currently
available to patients of lung, pancreatic, and other cancers. In
nonsmoker and East Asian lung cancer patients, mutations at
the EGFR kinase domain are particularly common (Sharma and
Settleman, 2009; Mitsudomi and Yatabe, 2010), and their pres-
ence is positively correlated with the success of treatment by
EGFR-kinase inhibitors, including gefitinib and erlotinib (Lynch
et al., 2004; Paez et al., 2004; Pao et al., 2004). L834R, which
accounts for 40% of such mutations, is the most commonly
observed single-residue mutation in this group (Figure 1A).
(This mutation is also referred to as L858R, corresponding
to an EGFR residue-numbering scheme that includes the
24-residue membrane-targeting signal sequence; the conven-
tion used in this study excludes those residues, which are
deleted in the mature protein.)
In light of the clinical importance of the L834Rmutation in lung
cancer, understanding the unique properties of the mutant
kinase is crucial to lung cancer biology and to drug development.
More generally, understanding how cancer mutants of a protein
differ from each other and from the wild-type at a molecular level
may potentially lead to personalized cancer treatment tailored
according to the genetic makeup of a cancer patient.
It has been well established that the activation of wild-type
EGFR is primarily driven by ligand-binding-induced receptor
dimerization (Schlessinger, 2000). In vitro assays have shown
that L834R and other cancer mutants of EGFR kinase are enzy-
matically more active than the wild-type under comparable
conditions (Zhang et al., 2006; Yun et al., 2007). Thesemutations
are generally assumed to give rise to spontaneous kinase activa-
tion, eliminating the dependence of the cancer mutants on
dimerization for activation. It is thus puzzling that, in vivo, dimer-
ization remains necessary for robust activity of the L834Rmutant
(Zhang et al., 2007). In the present study, we use long-timescale
molecular dynamics (MD) simulations to compare the EGFR
wild-type and L834R, among other cancer mutants, in order to
probe the molecular mechanism that gives rise to aberrant
signaling.
EGFR activation depends on the formation of asymmetric
dimers (Zhang et al., 2006), in which one EGFR kinase (the
Figure 1. Schematic View of an EGF Receptor and the Three Conformational States of Its Kinase Domain
(A) A complete EGF receptor in cartoon representation. The key structural elements of the kinase domain are shown, along with the locations of the cancer
mutations discussed here.
(B) An EGFR kinase monomer in the conformation that exhibits intrinsic disorder at the aC-helix region. The aC helix is largely dissolved and the catalytically
important Lys721–Glu738 salt bridge is broken, whereas the b9 strand is intact.
(C) An EGFR kinase in the Src/CDK2-like inactive conformation, where the aC helix is packed against a short helix that takes the place of the b9 strand.
(D) An activated EGFR kinase in an asymmetric dimer. The active conformation is distinguished by the intact Lys721-Glu738 salt bridge. Next to the cartoons in
(B–D) are ribbon renderings of the corresponding conformations of the aC helix region, with Lys721, Glu738, and the distance between these two residues shown.‘‘activator’’) stabilizes the other (the ‘‘receiver’’) (Figure 1D) in
the ‘‘aC-in active’’ conformation, which is characterized by
placement of the aC helix such that the catalytically important
KE salt bridge between Lys721 and Glu738 is maintained.
EGFR kinase also adopts the ‘‘aC-out inactive’’ conformation
(Wood et al., 2004; Jura et al., 2009), in which the aC helix is dis-
placed and the KE salt bridge is broken. This conformation is
frequently referred to as the ‘‘Src/CDK2-like inactive’’ conforma-
tion for its resemblance to the inactive conformations of Src and
CDK2 kinases (Figure 1C).
In this study, we observe the presence of a functionally impor-
tant third conformation, in which EGFR kinase exhibits local
intrinsic disorder (partial unfolding) at the region of the receiver
interface, particularly at the aC helix (Figure 1B). Intrinsic
disorder is widely known to play an important role in the function
of signaling proteins (Dunker et al., 2002). Although EGFR
signaling involves multiple layers of controlling mechanisms,
our identification of an intrinsically disordered state of EGFR
kinase introduces another element that may be critical for its
function. Our simulations suggest that the oncogenic L834R
mutation may cause aberrant activity by suppressing the local
intrinsic disorder, increasing the dimerization affinity of EGFR
and thus lowering the threshold for EGFR activation. Confirming
our computational predictions, we show that the L834R mutant
exhibits a much higher dimerization affinity than wild-type and
provide evidence that the higher overall activity of the L834R
mutant is due primarily to its propensity to dimerize. We also
show that the intrinsic disorder of EGFR may be similarly sup-
pressed by the phosphorylation of Tyr845 in the activation
loop, suggesting that Tyr845 phosphorylation may regulate the
autonomous lateral propagation of EGFR signals, a mechanism
by which signals are transmitted from one EGFR molecule toanother without requiring the binding of growth factors (Verveer
et al., 2000).
RESULTS
Lapatinib Binding Kinetics Suggests a Third
Conformation of EGFR Kinase
We found an initial indication of the existence of a third EGFR
kinase conformation by performing a computational study of
drug binding kinetics. In particular, we simulated the binding to
EGFR kinase of lapatinib (Movie S1 available online), a drug
known for its unusually slow binding kinetics (Wood et al.,
2004). Lapatinib, which is used to treat breast cancer and other
solid tumors, is known to bind to EGFR and Her2 kinases in the
Src/CDK2-like inactive conformations.
We initiated simulations with lapatinib molecules positioned at
random around an unliganded EGFR kinase in the Src/CDK2-like
inactive conformation. In four separate simulations with a total
duration of 47 ms, lapatinib bound to EGFR twice, in each case
adopting a bound pose virtually identical to that observed crys-
tallographically (Figure 2). These two binding events each
occurred after 7 ms of simulation; the remaining two simula-
tions, in which no binding event occurred, totaled 25 ms. These
simulations imply an on-rate of3.1 s1mM1 (or >0.83 s1mM1
with 90% confidence) for lapatinib biding to EGFR, which is
significantly higher than the experimentally derived on-rate of
0.02 s1mM1 (3.0 nM dissociation constant and 300 min
half-life for the EGFR-lapatinib complex [Wood et al., 2004]).
We believe this large discrepancy is unlikely to be entirely
attributable to simulation artifacts, because a number of other
ligand binding simulations have produced reasonably accurate
binding kinetics (Shan et al., 2011; Dror et al., 2011). In this study,Cell 149, 860–870, May 11, 2012 ª2012 Elsevier Inc. 861
Figure 2. Simulations of Lapatinib Binding to EGFR
Kinase
(A) The root-mean-square deviation (rmsd) of lapatinib’s
position in the binding simulations with respect to its
crystallographically determined native pose. The rmsd is
calculated based on the alignment of the protein confor-
mationwith respect to thecrystal structure.The inset shows
snapshots of lapatinib during a simulation color-coded by
the simulation time. Note that lapatinib enters its binding
pocket between the hinge region and the P loop, the only
persistent gateway to the binding site (see Movie S1).
(B) The simulation-generated lapatinib binding pose
compared with that of the crystal structure (PDB entry
1XKK). The methylsulfonyl group extends beyond the
ATP-binding site of EGFR kinase, and our simulations find
it to be themost flexible part of lapatinib in the bound state.
The protein is cropped to show lapatinib clearly. For
related simulations of gefitinib binding to EGFR, see also
Figure S1.we also performed similar simulations involving gefitinib, another
cancer drug that differs from lapatinib in that it binds to the active
aC-in conformation of EGFR. These simulations, with the kinase
in its aC-in conformation, not only captured the correct gefitinib
binding pose (Figure S1), but led to an estimated binding on-rate
(5.9 s1mM1, or >2.2 s1mM1 with 90% confidence) close to
gefitinib’s experimentally derived on-rate of 6.23 s1mM1
(0.19 ± 0.11 nM dissociation constant and 9 min half-life for the
EGFR-gefitnib complex [Gilmer et al., 2008]).
Our simulations suggest that the slow kinetics of lapatinib-
EGFR binding are due not to intrinsic properties of the Src/
CDK2-like inactive conformation, but instead to a rate-limiting
transition of EGFR kinase from some other, predominant confor-
mation to the Src/CDK2-like inactive conformation. If this is the
case, thispredominantconformationcouldnotbe theaC-inactive
kinase conformation because EGFR kinases are enzymatically
weak inmonomeric form.We thus suspect the presence of a third
EGFRkinaseconformation, and in the followingdiscussionwewill
attempt to elucidate the structural properties and functional
significance of this third conformational state of EGFR kinase.
Simulations Suggest Local Intrinsic Disorder of EGFR
Kinase, but Not of Src Kinase
The activation of EGFRkinasedepends on the formation of active
dimers, in which the C lobe of the activator kinase interacts with
the N lobe of the receiver, stabilizing the catalytically active
conformation of the latter (Figure 1D). We began by simulating
monomeric EGFR kinase from its active conformation, with the
expectation that, in the absence of the activator kinase, a confor-
mational change from the aC-in conformation would occur
over a timescale of microseconds to milliseconds, as is typical
of large-scale protein conformational changes (Kay, 1998).
Surprisingly, the EGFR kinase repeatedly escaped the aC-in
conformation on a much shorter timescale of 100 ns (Fig-
ure 3A), transitioning to an aC-out conformation (Figure 3B) that
differs from the Src/CDK2-like (aC-out) inactive conformation.
How is such an unusually fast conformational change real-
ized? The presence of fast conformational-change kinetics is
often associated with intrinsic disorder (e.g., Baker et al.,
2007). Our simulations consistently show that in leaving the initial862 Cell 149, 860–870, May 11, 2012 ª2012 Elsevier Inc.aC-in conformation, the EGFR kinase arrives at a state in which
the aC-helix region of the receiver interface is conformationally
disordered. In this state, the KE salt bridge is broken and the
aC helix itself is partially unfolded (Figure 3B). In contrast, the
activator interface at the C lobe of EGFR kinase remains stable
(Figure S2H).
To the best of our knowledge, the intrinsic disorder of EGFR
kinase has not been discussed previously, but our survey of
crystal structures finds supporting evidence for intrinsic disorder
in EGFR kinase. In particular, the crystal structure (Protein Data
Bank [PDB] entry 2RF9) of EGFR kinase (Figure 3B; Zhang et al.,
2007) is highly consistent with the disordered state we identified;
the unresolved region in the crystal structure coincides with
the disordered region in our simulations, and the conformation
of the resolved region is consistent with that observed in our
simulations in terms of the position of the ordered portion of
the aC helix and the intact b9 strand.
Traces of the intrinsic disorder in EGFR are also reflected in B
factors: the vicinity of the putatively disordered region (the
N-terminal part of the aC helix, the b3–aC loop, the P loop,
and the activation loop) exhibits the highest B factors in EGFR
crystal structures (Figure 3C).
In addition, we carried out simulations of Src kinase, a
prototypical tyrosine kinase. In contrast to EGFR, the aC-in
conformation of Src remained stable in 10-ms simulations. The
KE salt bridge was maintained throughout the simulation (Fig-
ure 3A). We also performed an independent bioinformatics
analysis and found it to predict the presence of intrinsic disorder
at the aC-helix in EGFR (particularly the part N-terminal to
Glu738), but not in that of Src (Figure 3D).
The crystallographic evidence discussed above supports the
idea that EGFR may feature a partially disordered state and that
our simulations are sufficiently accurate to distinguish between
kinases with and without the disorder. Hydrogen/deuterium (H/D)
exchange experiments lend further support to this conclusion.
H/D Exchange Measurements Confirm Local Disorder
of EGFR Kinase
To verify the presence of intrinsic disorder in EGFR kinase, H/D
exchange experiments were performed to characterize the
dynamic properties of both EGFR and Src kinases. The resulting
data lends further support to the notion of a unique, intrinsic
disorder at the aC helix region of the EGFR kinase. Consistent
with the notion that EGFR kinases primarily function in dimer
forms, H/D measurements demonstrate that monomeric EGFR
kinase, which has higher H/D exchange rates overall, is signifi-
cantly more dynamic than Src (Figure S2F). Indeed, the H/D
exchange rates of EGFR are significantly higher at the vicinity
of the receiver interface (the C-terminal portion of the aC helix,
the aC–b4 loop, and the b4 and b5 strands; Figure 3F). Distinctive
differences are also seen at the aE helix, the catalytic loop, and
the residues between the HRD and the DFG motifs. These resi-
dues are adjacent either to the C-terminal of the aC helix (the
C-terminal part of the aE helix and part of the catalytic loop), or
to the hinge region that controls the relative motions of the N
and the C lobes and the conformation of the ATP-binding site.
The Inferred Free-Energy Landscape of EGFR Kinase
Src and CDK2 kinases feature a two-basin free-energy land-
scape (Banavali and Roux, 2009; Berteotti et al., 2009) in which
a significant free-energy barrier separates the two basins, which
correspond to the active and the inactive conformations. Transi-
tions between these conformations require that this barrier be
crossed, a process that takes place on a timescale of microsec-
onds to milliseconds. The energy landscape may be altered to
favor the active conformation by protein-protein interactions or
by phosphorylation.
Our simulations, however, suggest a distinctive three-state
energy landscape for monomer EGFR kinase (Figure 3E). As dis-
cussed previously, the active conformation is highly unstable in
wild-type EGFR, suggesting that this conformation has a high
free energy. In addition, the fact that transitions from the active
to the disordered state occur on a nanosecond timescale implies
a downhill transition with minimal energetic barriers—that is, the
typical energetic basin for the active conformation is absent. On
the other hand, there is a well-formed basin corresponding to the
Src/CDK2-like inactive conformation; as a result, EGFR kinase
remains stable in this conformation for as long as 100 ms in simu-
lation (Figure S2E). Because the disordered and Src/CDK2-like
inactive conformations do not interconvert on the simulation
timescale, we are unable to determine which is more stable.
The slow lapatinib binding kinetics, which imply that binding
involves a rate-limiting conformational change toward the Src/
CDK2-like inactive conformation, suggest that the disordered
conformation, rather than the Src/CDK2-like inactive conforma-
tion, is likely predominant in monomeric EGFR kinases.
An important feature of this putative three-state energy land-
scape is the relatively high free energy associated with the active
conformation, which should hinder EGFR dimerization, given
that EGFR kinases need to adopt the active conformation
in the formation of asymmetric dimers. The high free energy of
the active conformation of EGFR kinase may be explained by
the relatively large patch of solvent-exposed hydrophobic
surface (590 A˚2) at the receiver dimer interface (Figure S2D),
which is much larger than the corresponding hydrophobic patch
(360 A˚2) in Src. This is confirmed by MD simulations of EGFR
kinase solvated by a mixture of water and isopropyl alcohol
(iPrOH), a simulation procedure originally designed for the iden-tification of potential drug-binding sites on protein surfaces
(Seco et al., 2009). Notably, the active conformation is stabilized
in this simulation, and the local intrinsic disorder is suppressed
by the aggregation of isopropyl alcohol (iPrOH) molecules at
the receiver and activator interfaces (Figures S2A–S2D). This
observation also suggests that the dimerization of EGFR kinase
is driven largely by a hydrophobic effect, as is typical of protein-
protein interactions (Lo Conte et al., 1999).
The Intrinsic Disorder of the Receiver Kinase Is
Suppressed in the Activated Dimer
Wild-type EGFR kinases by themselves exist predominantly as
monomers (Figure 4), indicative of a free-energy cost associated
with their dimerization. The overlap of the disordered region and
the receiver interface suggests a folding-upon-binding process
(Levy et al., 2005; Mittag et al., 2010; Wright and Dyson, 2009)
for the dimerization of EGFR kinases, in which the receiver kinase
adopts a specific, ordered conformation upon binding. Indeed,
simulations of the asymmetric dimer suggest that dimerization
suppresses the intrinsic disorder at the receiver interface, stabi-
lizing the active conformation of the receiver kinase (Figure 5A).
As a result, the KE salt bridge is stable in the receiver kinase, but
not in the activator. Conversely, we anticipate that allosteric
stabilization of the dimer interface through suppression of the
intrinsic disorder would promote dimerization.
L834R Allosterically Suppresses the Disordered State
and Promotes Dimerization
From crystal structures of a number of EGFR kinase mutants,
which broadly resemble those of the wild-type (Yun et al.,
2007, 2008), it is not immediately clear how the L834R mutation
alters the function of EGFR. Several molecular dynamics studies
have been carried out at a nanosecond timescale to investigate
the characteristics of L834R and other cancer mutants (Liu et al.,
2006; Papakyriakou et al., 2009; Dixit and Verkhivker, 2009), the
results of which suggested that the cancer mutations may favor
the active aC-in conformations and disfavor the Src/CDK2-like
inactive conformation, but have not raised the possibility of an
additional, disordered conformation.
In microsecond-timescale simulations, we found that transi-
tions from the aC-in active conformation to the disordered
conformation take place far more slowly in the L834R mutant
than in the wild-type, suggesting that the L834R mutation stabi-
lizes the aC-in active conformation relative to the disordered
state. In the L834R mutant, the positively charged Arg834 was
surrounded by a cluster of negatively charged residues
(Glu734, Asp831, and Asp813). As a result of these favorable
interactions, the aC helix exhibited higher stability and the KE
salt bridge remained intact for 2–30 ms, as opposed to tens of
nanoseconds for the wild-type (Figures 5C and S4). Although
these observations are kinetic in nature, they likely reflect an
underlying change of the free-energy landscape due to the
L834R mutation (Figure 3E). Overall, such a change favors the
active conformation at the expense of the disordered state and
as a result promotes EGFR dimerization.
Confirming our prediction of higher dimerization affinity of the
L834R mutant than the wild-type, light scattering and native gel
show that wild-type EGFR kinases generally exist as monomersCell 149, 860–870, May 11, 2012 ª2012 Elsevier Inc. 863
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Figure 3. Intrinsic Disorder in the aC Helix Region of EGFR Kinase
(A) Stability of the Lys721-Glu738 salt bridge inMD simulations. This salt bridge is highly unstable in EGFRmonomers, in sharp contrast to Src and CDK2 kinases.
The inset is an enlargement of the first 40 ns of the EGFR plots.
(B) The locally disordered conformation captured by X-ray crystallography. The orange represents a crystal structure (PDB entry 2ITP) of the active conformation
(the starting point of the simulations). The blue ribbon represents the crystal structure (PDB entry 2RF9) that resembles the simulation-generated disordered
conformation (red), in which part of the aC helix is disordered and the Lys721-Glu738 salt bridge is disrupted while the b9 strand is intact. The blue dashed line
represents the unresolved region in the crystal structure.
(C) B factors of EGFR crystal structures. The N-terminal portion of the aC helix, the b3–aC loop, the P and the activation loop are consistently the regions of high
flexibility as suggested by the high B factors (red).
(D) Bioinformatics analysis (Schlessinger and Rost, 2005) predicts intrinsic disorder at the aC helix for EGFR kinase but not for Src and CDK2.
(E) Cartoons of the inferred free-energy landscapes of wild-type EGFR kinase and mutants. Note that the free energy of the active conformation is lowered by
EGFR cancer mutations.
(F) Region-specific hydrogen/deuterium (H/D) exchange rates of EGFR and Src kinase in the vicinity of the aC helix. The residues in EGFR kinase that are involved
in the receiver interfaces of the asymmetric dimer and their corresponding residues in Src are highlighted. The exchange rates of the disordered region of EGFR
864 Cell 149, 860–870, May 11, 2012 ª2012 Elsevier Inc.
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Figure 4. Experimental Evidence for Enhanced L834R Dimerization
(A) Static light scattering analyses of the wild-type kinase and the L834Rmutant. Protein peaks monitored by reflective index are plotted as solid lines against the
elution volume. Molecular weight distribution of protein peaks calculated from light scattering data are plotted as dots. The wild-type kinase runs as a single peak
with a molecular weight (40.47 kDa) comparable to that of the kinase monomer (37.5 kDa). The L834R mutant displays multiple peaks. The average molecular
weights of the two right peaks match those of the L834R monomers and dimers. The molecular weights of the larger species (the peaks on the left side) were not
calculated due to high polydispersity.
(B) Native gel analysis of EGFR wild-type and L834R mutant (four lanes each).
(C) The concentration dependence of specific activities. The data (red dots) fit well to the dimerization-activation model (the dashed curve). Dimerization affinity
(Kd) and intrinsic catalytic potency may be estimated from the fitting. The latter are 0.09 s
1, 0.21 s1, 0.01 s1, and 0.0013 s1 for EGFR wild-type, L834R and
Y845E mutants, and Her2 kinase, respectively. Consistent with an earlier report (Monsey et al., 2010), the activity of Her2 kinase is relatively weak. The activity of
L834R at 18 mMwas underestimated presumably due to substrate/ATP depletion in the measurement and is ignored in the curve fitting. For the denaturing gel of
the protein samples used in the enzymatic assays, see also Figure S3.whereas L834R proteins preferentially form dimers and oligo-
mers in solution (Figures 4A and 4B). From light scattering, the
inferred molecular weights of L834R are consistent with those
of monomers or dimers. In contrast, the inferred molecularkinase are significantly higher than those of the corresponding region in Src. The H
the data represents an incubation time; from top to bottom, the incubation times
300, and 1,000 s. For additional H/D exchange data, the stability of the Src-like
alcohol on EGFR kinase, see also Figure S2.weights of the wild-type correspond only to monomers. Consis-
tent with these findings, in our native gel analysis the L834R
mutant exhibited a striking ladder-like pattern, indicating the
presence of the asymmetric dimers and even higher-order/D exchangemeasurements were carried out at pH 6.0 and pH 7.0. Each row of
at pH 6.0 are 30, 100, 300, 1,000, and 3,000 s, and those at pH 7.0 are 30, 100,
conformation or the activator interface, and the stabilizing effect of isopropyl
Cell 149, 860–870, May 11, 2012 ª2012 Elsevier Inc. 865
AB
C
D
Asp831
Asp813
lle744
Figure 5. Asymmetric Dimerization, Tyr845 Phosphorylation, and
Cancer Mutations Suppress Intrinsic Disorder
(A) Stability of the active conformation in the asymmetric dimer of EGFR
kinase. Plots of the Lys721–Glu738 distance show that the KE salt bridge in the
receiver kinase is stabilized, in contrast to that in the activator.
(B) Phosphorylation of Tyr845 of the activation loop. Simulations show that
a monomeric EGFR kinase with phosphorylated Tyr845 (pTyr845 as shown)
forms a stable interaction with Lys836, resulting in the stabilization of the active
conformation and the aC helix. Note that the Lys836–pTyr845 interaction is
conserved in many phosphorylated protein tyrosine kinases.
(C and D) In the left panels, the main interactions of the mutated residues in
cancer mutants L834R and S744I are shown. KE salt bridge remained intact
much longer during simulations of these mutants than in simulations of the
wild-type. For the enhanced helicity at the aC-helix region due to cancer
mutations and Tyr845 phosphorylation, see also Figure S4.
866 Cell 149, 860–870, May 11, 2012 ª2012 Elsevier Inc.oligomers, whereas the wild-type ran as a single band, presum-
ably as monomers (Figure 4B). The L834R oligomers are
possible because the asymmetric dimers are open-ended
structurally.
Additionally, H/D exchange experiments were carried out on
the L834R mutant as well as the wild-type. The resulting H/D
exchange profiles (Figure S2G) do not obviously distinguish
the wild-type from the mutant, suggesting that the disordered
state remains predominant in the mutant. This finding is con-
sistent with our simulation of L834R, in which the disordered
state was eventually reached, albeit after a substantially longer
time than for the wild-type (Figure 5C). Given the limited sensi-
tivity of H/D exchange experiments to changes in the fraction
of a slowly exchanging minority state, the H/D exchange results
appear consistent with the inference drawn from simulations
that the mutation lowers the free energy of the minority (active)
state toward that of thepredominant disordered state (Figure 3E).
Further simulations of L834R in the Src/CDK2-like inactive
conformation show that Arg834 engages in favorable interac-
tions (Figure S2E) and stabilizes this conformation, rather than
destabilizing it as some previous studies have suggested. It is
thus unlikely that the cancer mutation stabilizes the active
conformation at the expense of the Src/CDK2-like inactive
conformation. Instead, stabilization of the active conformation
is likely achieved at the expense of the disordered conformation.
The impact of the L834R mutation on the activator interface,
compared to the receiver interface, appears limited. It was
shown (Zhang et al., 2007) that, like the wild-type, the activity
of the kinase-dead and activator-only L834R mutant (D813N/
I682N/L834R) cotransfected with the receiver-only mutant
(V924R) remains dependent on EGF stimulus, indicating that
the L834Rmutation does not affect the activator interface signif-
icantly. In contrast, when the L834Rmutation is introduced to the
receiver-only mutant, as in cotransfection of I682N/D813N/
L834R and V924R/L834R, the activity becomes much higher in
absence of EGF, reflecting the impact of the L834R mutation
on the receiver interface. Consistent with these findings, simula-
tions showed that the conformational dynamics of the region of
the activator interface of the L834R mutant does not differ from
the wild-type in any obvious way (Figure S2I).
Elevated Dimerization Affinity Underlies the Aberrant
Activity of L834R
Consistent with an elevated dimerization affinity, enzymatic
assays show that L834R reaches its peak kinase activity at a
much lower concentration than does the wild-type (Figures 4C
and S3A). As a result, the threshold for activation is lower and
the cancer mutant is catalytically more active than the wild-
type, especially at relatively low concentrations. The assays
further show that the aberrant activity of the L834R cancer
mutant in the absence of an EGF signal may arise primarily
from the higher dimerization affinity than from the modest
(2-fold) increase in intrinsic catalytic potency (estimated to be
0.21 s1 for L834R as opposed to 0.09 s1 for the wild-type).
At 25 nM concentration, for example, L834R is as much as
60 times more active than the wild-type (specific activity of
0.042 s1 compared to 0.00066 s1); this difference is thus
predominantly attributable to the change of dimerization affinity
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Her2            VPIKWMALESILRRRFTHQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQ
Her4            MPIKWMALECIHYRKFTHQSDVWSYGVTIWELMTFGGKPYDGIPTREIPDLLEKGERLPQ
iEGFR           MPIKWLALECIRNRVFTSKSDVWAFGVTIWELLTFGQRPHENIPAKDIPDLIEVGLKLEQ
EGFR            PPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGD  961 
Her2            PPICTIDVYMIMVKCWMIDSECRPRFRELVSEFSRMARDPQRFVVIQNE
Her4            PPICTIDVYMVMVKCWMIDADSRPKFKELAAEFSRMARDPQRYLVIQGD
iEGFR           PEICSLDIYCTLLSCWHLDAAMRPTFKQLTTVFAEFARDPGRYLAIPGD
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Figure 6. Stability of the Active Conformation in Her2, Her4, and
iEGFR Kinases
(A) Sequence alignment of EGFR, Her2, Her4, and iEGFR. The sequence
identities to EGFR kinase are marked by the blue background.
(B) The KE salt bridge remained intact during 20-ms simulations of Her2, Her4,
and iEGFR kinases, whereas it quickly broke in simulations of EGFR kinase.by the cancer mutation. The increased activity of L834R, due to
higher dimerization affinity, rather than to an increase in intrinsic
catalytic potency, explains the need for EGFR dimerization for
robust autophosphorylation of the L834R mutant in vivo, as it
is for the wild-type (Zhang et al., 2007).
Simulations of Other Cancer EGFR Mutants
Besides L834R, we have studied a number of additional EGFR
cancer mutants that have been identified in NSCLC patients,
including S744I, G695S, L837Q, and Del722–726, which entails
a five-residue deletion of residues 722–726. Although the
mutation sites vary, our simulations suggest that in these
mutants, as in L834R, the active aC in conformation is stabilized
compared to the wild-type (Figures 5 and S4). Presumably,
both Del722–726 and G695S rigidify the b3–aC loop and reduce
the local disorder at the aC-helix region—the former by short-
ening the b3–aC loop and the latter by reducing the flexibility
of the P loop, which is dynamically coupled with the b3–aC
loop. L837Q and S744I mutations most likely enthalpically stabi-
lize the active aC-in conformation by engaging with the residues
of the aC helix and residues of the adjacent b9 strand respec-tively. L837Q allows new hydrogen bonds near the C-terminal
of the aC helix, whereas S744I improves hydrophobic packing
between the aC helix and the b9 strand.
Active Conformations of Her2 and Her4 Kinases Display
Increased Stability
What is the functional role of the disorder? Extension of this
study from EGFR to other members of EGFR family may help
answer this question. We thus examined whether the disorder
may be observed in Her2 and Her4 kinases, which both share
81% sequence identity with EGFR and a similar activation
mechanism (Monsey et al., 2010). (Her3 is a pseudokinase that
dimerizes with the other receptors of the EGFR family [Paez
et al., 2004] as an activator.) We also considered cyclin-depen-
dent kinase 2 (CDK2), because the way in which the activator
kinase activates the receiver in EGFR resembles the way in
which cyclin A activates CDK2 (Zhang et al., 2006); CDK2 and
the receiver EGFR kinase appear to exploit similar protein-
protein interfaces at similar locations.
Because of the close homology, one might expect Her2
dynamics to be highly similar to EGFR. In our simulation of
Her2 kinase, however, the local intrinsic disorder was not
observed; the aC-in conformation remained stable throughout
a 20-ms simulation (Figure 6). The more stable receiver interface
of Her2 allowed the kinase to dimerize more readily, consistent
with the role of Her2 as a preferred heterodimeric partner.
Her2 activity assays (Figure 4C) show that Her2 dimerizes
more readily than EGFRwild-type. Because the residues directly
in contact with the other monomer in an active dimer are highly
conserved between Her2 and EGFR, this difference in dimeriza-
tion may only be attributed to the difference in the conforma-
tional stability required for the dimerization.
Simulations of Her4 also show a stable aC-in conformation
and the absence of local intrinsic disorder (Figure 6). This
contrast between Her2 and Her4 on the one hand and EGFR
on the other suggests that EGFR kinase is unique in the family
for its pronounced intrinsic disorder at the receiver interface.
A stable aC-in conformation is observed in CDK2 kinase as
well, despite the fact that the activation of CDK2 kinase resem-
bles EGFR activation structurally (Figure 3).
DISCUSSION
EGFR dimerization, which leads to catalytic activation and
subsequent EGFR signaling, is driven primarily by the binding
of growth factors to the extracellular segment of the receptor.
Some EGFR components, such as the transmembrane and the
juxtamembrane segments, are known to promote dimerization
(Mendrola et al., 2002; Jura et al., 2009). On the other hand,
the extracellular segments are disinclined to dimerize without
the binding of growth factors (Odaka et al., 1997), and our exper-
iments have shown that the dimerization affinity of the cyto-
plasmic kinase domains is weak. These components contribute
to a bias against EGFR dimerization in the absence of EGF. Even
with EGF bound, the extracellular segments of EGFR dimerize
with a moderate affinity of Kd z 2.4 mM (Odaka et al., 1997;
Burgess et al., 2003; Ogiso et al., 2002). The energetic balance
controlling EGFR dimerization is thus delicate: the bias againstCell 149, 860–870, May 11, 2012 ª2012 Elsevier Inc. 867
Figure 7. A Model for EGFR Lateral Signal Propagation
A cartoon model for lateral propagation based on Tyr845 phosphorylation. The
EGF-bound dimer (center) is activated first. In addition to phosphorylating the
C-terminal tails of the EGFRs and setting off a downstream signal cascade,
this activated dimer may promote secondary dimerization and autonomous
activation (independent of EGF binding) by phosphorylating other EGFR
kinases at Tyr845. Such a process may be self-sustained and may be atten-
uated by protein tyrosine phosphatases.dimerization is sufficiently weak that it may be overcome by the
moderate affinity increase due to EGF binding.
In this context, we suggest that the intrinsic disorder of
the kinase domain may be critical to the overall balance that
dictates EGFR dimerization and ultimately regulates EGFR
signaling. Cancer mutations that allosterically suppress the
intrinsic disorder shift the balance toward EGFR dimerization
and consequently alter EGFR basal activity and the intensity
and duration of EGFR signaling in response to an EGF stimulus.
We note that the higher kinase activity of the EGFR L834R cancer
mutant (relative to the wild-type) owes more to a decreased
threshold for dimerization-mediated activation than to the
enhanced intrinsic catalytic potency of the mutant. In other
words, the mutant is predisposed to dimerize.
Protein kinase domains are known to exhibit complex confor-
mational dynamics in regulation and in catalytic cycles (Master-
son et al., 2010; Shan et al., 2009). Although EGFR kinase has not
previously been reported to display intrinsic disorder, intrinsi-
cally disordered proteins are prevalent, accounting for 15% of
all eukaryotic proteins (Ward et al., 2004). Because of its role in
complex molecular functions, intrinsic disorder is believed to
be evenmore prevalent among regulatory and signaling proteins
(Ward et al., 2004). It has been suggested that, among many
other functional roles (Tompa, 2010), intrinsic disorder allows
proteins to engage in weak, yet specific interactions with
multiple partners (Cortese et al., 2008), and it facilitates faster
kinetics of molecular recognition (Zhou, 2012). Intriguingly, the
intrinsic disorder in human EGFR kinase may be a more recently
evolved characteristic associated with more complex function.
Our simulation showed that the intrinsic disorder is apparently
absent in the more ancient invertebrate EGFR (iEGFR) kinase
in Drosophila melanogaster (Figure 6), which shares a 58%
sequence identity to its human counterpart.
If intrinsic disorder indeed plays a critical role in EGFR
activation, is this disorder regulated? In particular, might EGFR
dimerization be regulated not only extracellularly by ligand
binding but also cytoplasmically? Here we present a hypothesis868 Cell 149, 860–870, May 11, 2012 ª2012 Elsevier Inc.for such a cytoplasmic mechanism based on the phosphoryla-
tion of the kinase domains at Tyr845.
Tyr845 of EGFR kinase represents a highly conserved tyrosine
in the activation loop of protein tyrosine kinases. The phosphor-
ylation of this residue is typically involved in the activation of
a tyrosine kinase (Huse and Kuriyan, 2002). Although Tyr845
phosphorylation is not required for the activation of EGFR kinase
(Gotoh et al., 1992), it remains closely involved in the regulation
of EGFR function as well as in tumor progression (Khan et al.,
2008). In particular, Tyr845 phosphorylation has been observed
to follow an EGF stimulus (Choi et al., 2007; Qiu et al., 2009).
Y845F mutation is known to lead to dramatic ablation of EGF-
induced DNA synthesis (Biscardi et al., 1999) and to a significant
decrease in phosphorylation of the receptor (Huang et al., 2010).
It remains unclear, however, by what mechanism the phosphor-
ylation impacts EGFR signaling.
Our simulations demonstrated that Tyr845 phosphorylation at
the activation loop suppresses the intrinsic disorder and secures
the aC-in conformation (Figure 5). This effect appears to be real-
ized through the buttressing of the b9 strand via the salt bridge
between the phosphotyrosine and Lys836. As simulation work
on Her2 kinase has suggested, the activation loop and the aC
helix are generally coupled and phosphorylation at the activation
loop tends to favor the aC-in conformation (Telesco and Rad-
hakrishnan, 2009). Kinase assays on the Y845E mutant, where
the mutation is introduced as a mimic of the phosphorylation,
lends support to the simulation finding regarding Tyr845. The
assays showed that the mutation produces a modest increase
in the dimerization affinity (Figure 4C). Glutamate is known to
be an imperfect mimic of phosphotyrosine. Tyr845 phosphoryla-
tion is likely more potent than the mutation mimic in promoting
EGFR dimerization. In addition, in vivo data have shown that
the L834R mutation is associated with an elevated level of
Tyr845 phosphorylation (Choi et al., 2007), and thus it is tempting
to speculate that the effect of L834R is amplified by W845
phosphorylation.
In light of these findings, we propose a mechanism for lateral
signal propagation centered on Tyr845 phosphorylation. Unlike
the ‘‘vertical’’ signal propagation that is directly induced by
EGF binding, lateral propagation refers to the autonomous
signaling process arising from interaction among EGFRs them-
selves. Lateral signal propagation has been suggested to be
an integral part of EGFR signaling (Ichinose et al., 2004; Verveer
et al., 2000) and, in particular, signal amplification.
We propose that EGFR activation and Tyr845 phosphorylation
are part of a self-sustained signal propagation and amplification
process. In this proposed mechanism, extracellular ligand
binding initially leads to activation of a subset of EGFR mole-
cules. Other EGFRs may then be phosphorylated at Tyr845,
primed for dimerization, and consequently activated cytoplasmi-
cally (Figure 7). (It is not essential to this mechanism whether
Tyr845 phosphorylation in vivo is carried out through EGFR
autophosphorylation [Qiu et al., 2009] or through other kinases
[Biscardi et al., 1999].) In isolation this process might expand
exponentially, but in vivo it may be dampened by Tyr845
dephosphorylation by protein tyrosine phosphatases (PTPs),
the inhibition of which has been shown to promote lateral signal
propagation (Reynolds et al., 2003). If the role of Tyr845
phosphorylation in promoting EGFR dimerization is confirmed,
an interesting question may arise as to whether this could lead
to a mechanism for ‘‘inside-out’’ EGFR signaling.
EXPERIMENTAL PROCEDURES
We summarize our computational and experimental procedures below;
additional detail is provided in the Supplemental Information.
Molecular Dynamics
The simulations of EGFR kinase starting from the Src/CDK2-like inactive
conformation were based on PDB entry 2GS7. The simulations of lapatinib
and gefitinib binding were initiated from PDB entries 1XKK and 2ITO, respec-
tively. All other EGFR simulations were based on PDB entry 2ITP. The simula-
tions of Her2, Her4, CDK2, and Src kinases were based on PDB entries 3PP0,
3BCE, 1FIN, and 1Y57, respectively. We used the Anton specialized hardware
(Shaw et al., 2009) and the modified Amber99SB protein force field (Lindorff-
Larsen et al., 2010) to perform the simulations.
Hydrogen/Deuterium ExchangeMass Spectrometry and Static Light
Scattering
Hydrogen/deuterium exchange rates were measured using mass spectrom-
etry (Yoshitomo Hamuro, ExSAR, Monmouth Junction, NJ). Static light
scattering experiments were performed as described previously (Zhang
et al., 2006).
Kinase Activity Assays
Kinase activity was measured using radiometric assays (Edward Esposito,
Blue Sky Biotech, Worcester, MA). Poly(Glu4Tyr) substrate was used. The
EGFR constructs in these assays included residues 672–998; the Her2
construct included residues 705–1029. All constructs included an N-terminal
His tag.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures,
four figures, and one movie and can be found with this article online at
doi:10.1016/j.cell.2012.02.063.
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